Progress in Medicinal Chemistry
- 1st Edition, Volume 44 - April 25, 2006
- Imprint: Elsevier Science
- Editors: F.D. King, G. Lawton
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 4 - 5 1 7 3 7 - 1
- Paperback ISBN:9 7 8 - 0 - 4 4 4 - 5 4 7 4 5 - 3
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 4 6 2 1 0 - 3
The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being mat… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThe perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are ‘druggable’, is the best starting point for improved productivity.
The seven chapters of this volume describe recent progress towards drugs acting at a range of ‘druggable’ targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.
The seven chapters of this volume describe recent progress towards drugs acting at a range of ‘druggable’ targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.
*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect
Chemists, biologists, doctors, pharmacists and anyone interested in the contemporary controversy about drugs, drug firms, and the community
- Edition: 1
- Volume: 44
- Published: April 25, 2006
- No. of pages (Hardback): 404
- No. of pages (eBook): 404
- Imprint: Elsevier Science
- Language: English
- Hardback ISBN: 9780444517371
- Paperback ISBN: 9780444547453
- eBook ISBN: 9780080462103
FK
F.D. King
Affiliations and expertise
GlaxoSmithKline, Harlow, Essex, UKGL
G. Lawton
Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.
From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines.
Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities.
Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.
He is a founder of INMedD, a new medicines discovery social enterprise.
Affiliations and expertise
St. Ippolyts, Herts, UKRead Progress in Medicinal Chemistry on ScienceDirect